Sun Pharma Faces Delhi High Court Challenge For Semaglutide Tablet Launch

Market snapshot: Sun Pharma is facing a legal hurdle in its oral diabetes portfolio as the Delhi High Court has directed the company to obtain judicial approval before commercially launching its generic semaglutide tablets. The order follows a patent infringement suit filed by Danish innovator Novo Nordisk, which seeks to protect its proprietary formulation.

Data Snapshot

• Sun Pharma ranks first in the Indian pharmaceutical market with an 8.5% market share as of June 2026.
• Sun Pharma's generic semaglutide brands Sematrinity and Noveltreat registered combined net sales of ₹13 crore in India since their launch in March 2026.

What's Changed

• Sun Pharma's Indian pharmaceutical market share has risen to 8.5% as of June 2026, compared to 8.2% in the previous period.

Key Takeaways

• The Delhi High Court has directed Sun Pharma to seek explicit judicial clearance before commercially launching its oral semaglutide tablets in India.
• The patent litigation specifically concerns the oral formulation that uses Salcaprozate sodium (SNAC) to enhance stomach absorption.
• Sun Pharma has not yet secured a commercial manufacturing license for the semaglutide tablets.
• The company's existing injectable semaglutide brands, Noveltreat and Sematrinity, remain unaffected by this ruling.

SAHI Perspective

While this legal hurdle delays Sun Pharma's entry into the high-growth oral semaglutide market in India, it does not impact its current financials. Since Sun Pharma has not yet received a commercial manufacturing license for the tablets, there is no immediate loss of revenue. Furthermore, its injectable semaglutide portfolio is already active domestically, and the company is rapidly expanding its generic reach in international markets like South Africa and Brazil.

Market Implications

The ruling establishes a cautious environment for generic manufacturers targeting Novo Nordisk's oral formulations. While compound patents for semaglutide are expiring, secondary patents covering absorption-enhancing compounds like SNAC remain active defense mechanisms for innovators. This legal step will likely slow down oral generic launches in India but reinforces the reliance on injectable generics in the near term.

Trading Signals

Market Bias: Neutral

The Delhi High Court's restriction on oral semaglutide launch is a near-term sentiment hurdle, but has no immediate impact on earnings as Sun Pharma does not yet hold a manufacturing license for the tablets. The company's established injectable brands Sematrinity and Noveltreat, which posted ₹13 crore in net sales by July 2026, remain unaffected.

Overweight: Pharmaceuticals, Healthcare

Trigger Factors:

• Securing commercial manufacturing license for semaglutide tablets
• Outcome of the Delhi High Court patent infringement hearing
• Sales growth of existing injectable brands Noveltreat and Sematrinity

Time Horizon: Medium-term (3-12 months)

Industry Context

The global and domestic demand for semaglutide-based treatments for obesity and Type 2 diabetes has triggered intense competition. With major players like Dr. Reddy's and Alkem also entering the space, innovator Novo Nordisk is actively defending its IP. Sun Pharma, as the leading player in India's cardiometabolic therapeutic area, is leveraging its injectables while navigating legal pathways for oral alternatives.

Key Risks to Watch

• Adverse final judgment in the patent infringement suit could permanently block the launch of Sun Pharma's oral semaglutide tablets until patent expiry.
• Delays in obtaining the commercial manufacturing license for oral formulations.
• Increasing competition from domestic rivals who may bypass the specific patented oral absorption enhancers.

Recent Developments

In July 2026, Sun Pharma obtained regulatory approvals to manufacture and market its weekly injectable generic semaglutide in both South Africa and Brazil, expanding its footprint in global emerging markets.

Closing Insight

Legal battles over blockbuster drugs are typical for generic leaders. Sun Pharma's strong injectable portfolio and global approvals provide an immediate buffer against domestic legal delays on oral tablets.

High Performance Trading with SAHI.